Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Purple Biotech Ltd. announced the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering tri-specific antibody constructs under its CAPTN-3 platform. This patent strengthens the company's intellectual property protection for its modular multispecific antibody technology designed to accelerate development of cancer i…
Johnson & Johnson reportedly replaced $913 million in lost sales with $2.4 billion of new ones but retained less than half of that benefit. The market is near the 52-week high and technical momentum is soft. Valuation is full (market cap ~$654B, P/E ~31). For traders, that sets up a mid-term short: enter at $273.00, stop at $282.00, target $250.00 …
Berkshire Hathaway CEO Greg Abel said the expansion of AI data centers presents a material growth opportunity for the company’s energy operations. The remarks followed Berkshire’s recent increase in its Alphabet position, which Abel and Chairman Warren Buffett approved three months ago. Abel highlighted the electricity intensity of data centers and…
Simmons First National (SFNC) is a regional bank with a long dividend pedigree and a current share price trading below book. With a quarterly dividend of $0.215 (ex-dividend 09/15/2026), improving loan growth, and a cheap price-to-book of ~0.92, the stock offers a lower-risk entry for a mid-term swing trade. Enter at $22.24, stop at $20.00 and targ…
Edible Garden AG Incorporated has officially regained compliance with Nasdaq’s minimum bid price rule, enabling it to maintain its listing and focus on executing growth strategies including expanding its Webster City facility to manufacture ready-to-drink nutrition products and advancing its Farm-to-Formula® platform.
Fervo Energy’s headline 396 MW power deal with Google validates its technology, but the agreement also crystallizes capital intensity, timing risk and near-term revenue shortfalls that the market may have ignored. With a market cap around $5.8B and 2027 revenue guide down to $60-80M, FRVO looks stretched. This is a high-risk short idea with a clear…
Ollie’s Bargain Outlet shares rose in pre-market trading after the off-price retailer reported fiscal second-quarter results that significantly exceeded earnings expectations. The company delivered a large adjusted EPS beat, raised full-year profitability guidance, and executed sizable share repurchases, even as comparable-store sales declined and …
Fastly reported record Q2 revenue and is translating AI-driven traffic into higher-margin Security and Compute services. The market has punished the shares on short-term volatility and insider sales, creating a tactical long opportunity for patient traders that want to capture platform re-rating over the next 180 trading days.
Lifecore Biomedical has signed a significant agreement to perform tech transfer and commercial manufacturing for a commercially marketed injectable drug product from a global pharmaceutical company. This program, expected to generate revenue starting in 2028, further strengthens Lifecore's late-stage commercial pipeline and expands its customer bas…
uniQure has submitted a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorisation Application (MAA) to the U.K.'s MHRA for its investigational gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease. The applications are based on three-year Phase I/II study data showing slowed disease progression and the c…
Hewlett Packard Enterprise shares rose sharply in pre-market trading as investors positioned ahead of the company’s fiscal third-quarter 2026 earnings report. A pair of analyst moves - a Deutsche Bank Buy initiation with a $62 target and a Bank of America price-target increase to $82 - alongside hefty consensus growth expectations and a significant…
Teva Pharmaceutical Industries announced positive topline Phase 2a study results for TEV-408, an investigational anti-IL-15 antibody. The drug showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage in celiac disease patients, with a favorable safety profile. TEV-408 also demonstrated a reduction in…
European Wax Center, a leading US waxing services franchisor, has introduced the Golden Orchard Body Butter and Body Polish, limited-edition fall skincare products designed to hydrate, exfoliate, and nourish skin while reducing hair thickness between waxes, expanding its SLOW Hair Minimizing System.
Cardiff Oncology announced that their Ph.D. Mani Mohindru will present at the 8th Annual RAS-Targeted Drug Development Summit and participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company focuses on developing PLK1 inhibition therapies, including its lead candidate onvansertib, targeting RAS-mutated…
G-III Apparel Group reported second quarter fiscal 2027 net income per diluted share of $0.46, surpassing guidance and nearly doubling last year's $0.25. Despite a 10% decline in net sales due to Calvin Klein and Tommy Hilfiger license losses, gross margins expanded by 440 basis points. The company completed the acquisition of Marc Jacobs, targetin…
Maze Therapeutics, a clinical-stage biopharmaceutical company focused on small molecule precision medicines for kidney and metabolic diseases, announced that management will participate in three investor conferences in early to mid-September 2026, including Wells Fargo Healthcare Conference, Citi Biopharma Summit, and HC Wainwright Global Investmen…
TScan Therapeutics announced a strategic reorganization to concentrate resources on developing in vivo engineered TCR-T cell therapies for solid tumors, advancing two candidates toward IND-enabling studies and planned Phase 1 trials by late 2027. Due to insufficient capital, the company has paused enrollment in the Phase 3 ALLOHA-2 study for TSC-10…
Tilray Brands, Inc. announced that due to strong consumer demand, its Popsicle Hard Firecracker flavor, originally a limited-edition seasonal product, will become a permanent offering in the Popsicle Hard malt beverage lineup. This move reflects the brand's strategy to leverage nostalgia-driven flavors to capture growth in the adult flavored bevera…
Ollie’s Bargain Outlet Holdings, Inc. announced its second quarter fiscal 2026 financial results, revealing a 9.1% increase in net sales to $741.3 million driven by new store openings and growth in loyalty members. Comparable store sales declined 1.8% due to challenging economic conditions, weather impact, and a competitive promotional environment.…
GXO Logistics, the world's largest pure-play contract logistics provider, announced that its executive leadership will participate in upcoming investor conferences, including the Jefferies Global Industrials Conference and the Morgan Stanley 14th Annual Laguna Conference. The company will showcase its strategies and business updates through present…
EyePoint, Inc. (Nasdaq: EYPT), a clinical-stage biopharmaceutical company focused on retinal diseases, announced its active participation in several upcoming investor conferences and The Retina Society 59th Annual Scientific Meeting, where it will present data on its lead product candidate DURAVYU (EYP-1901). DURAVYU is a sustained delivery treatme…
Fortrea has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials, including a clinical pharmacology unit, bioanalytical laboratory, and biospecimen storage facilities in Texas. This acquisition strengthens Fortrea’s integrated clinical development platform from first-in-human studies through Phase …
Opus Genetics announced it will present topline data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 gene therapy targeting BEST1-related inherited retinal diseases. The data presentation is scheduled for September 9, 2026, followed by full clinical datasets at major ophthalmology conferences. OPGx-BEST1 uses an AAV vector to deliver a functiona…
FactSet will release its financial results for the fourth quarter of fiscal 2026 on September 30, 2026, followed by a conference call to discuss the results. The earnings presentation and a replay will be accessible on the company's Investor Relations website.
VEON Ltd. will release its consolidated financial and operating results for Q3 2026 on November 6, 2026, followed by a conference call with senior management. Additionally, the company will hold a Capital Markets Day on November 16, 2026, to discuss strategic priorities, business performance, and long-term value creation.
